Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes - Concepedia

Concepedia

Publication | Open Access

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

DOI Full Paper Access

361

Citations

43

References

2005

Year

Andrea Mari, William M. Sallas, Yanling He, C. E. Watson, Monica Ligueros‐Saylan, Beth E. Dunning, Carolyn F. Deacon, Jens J. Holst, James E. Foley

The Journal of Clinical Endocrinology & Metabolism

Abstract

Vildagliptin is an incretin degradation inhibitor that improves beta-cell function in diabetic patients by increasing the insulin secretory tone.

References

	Year	Citations

Page 1